Effects of HIV aspartyl-proteinase inhibitors on Leishmania sp.

Experimental Parasitology

Volumn 126, Issue 4, 2010, Pages 557-563

  Valdivieso, Elizabeth ^a   Rangel, Ariadne ^a   Moreno, Javier ^b   Saugar, Jose María ^b   Cañavate, Carmen ^b   Alvar, Jorge ^b   Dagger, Francehuli ^a  

^a FACULTAD DE CIENCIAS   (Venezuela)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Ac Leu Val Phenyalaninal; Aspartyl proteinase; HIV; Leishmania; Nelfinavir; Saquinavir mesylate

Indexed keywords

AMINO ACID DERIVATIVE; ASPARTIC PROTEINASE; ASPARTIC PROTEINASE INHIBITOR; NELFINAVIR; SAQUINAVIR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR;

AMASTIGOTE; ANIMAL CELL; ANTIMICROBIAL ACTIVITY; ARTICLE; CELL DIVISION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEISHMANIA; LEISHMANIASIS; MACROPHAGE; MIXED INFECTION; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMASTIGOTE; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CELL LINE; COMPLICATION; DOSE RESPONSE; DRUG EFFECTS; ENZYMOLOGY; GROWTH, DEVELOPMENT AND AGING; HIV INFECTIONS; LEISHMANIA INFANTUM; LEISHMANIA MEXICANA; PARASITOLOGY;

ANIMALS; ASPARTIC ACID PROTEASES; CELL LINE; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; LEISHMANIA INFANTUM; LEISHMANIA MEXICANA; LEISHMANIASIS; MACROPHAGES; MICE; MONOCYTES; NELFINAVIR; SAQUINAVIR;

HUMAN IMMUNODEFICIENCY VIRUS; LEISHMANIA SP.;

EID: 79955666754     PISSN: 00144894     EISSN: 10902449     Source Type: Journal    
DOI: 10.1016/j.exppara.2010.06.002     Document Type: Article

References (38)

1. Alvar J., Cañavate C., Gutiérrez-Solar B., Jimenez M., Laguna F., Lopez-Velez R., Molina R., Moreno J. Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clinical Microbiology Reviews 1997, 10:298-319.
2. Alvar J., Croft S., Olliaro P. Chemotherapy in the treatment and control of leishmaniasis. Advances in Parasitology 2006, 61:223-274.
3. Alvar J., Yactayo S., Bern C. Leishmaniasis and poverty. Trends in Parasitology 2006, 22:552-557.
4. Alvar J., Aparicio P., Aseffa A., Den Boer M., Cañavate C., Dedet J.P., Gradoni L., Ter Horst R., López-Vélez R., Moreno J. The relationship between leishmaniasis and AIDS: the second 10 years. Clinical Microbiology Reviews 2008, 21:334-359.
5. Andrews K.T., Fairlie D.P., Madala P.K., Ray J., Wyatt D.M., Hilton P.M., Melville L.A., Beattie L., Gardiner D.L., Reid R.C., Stoermer M.J., Skinner-Adams T., Berry C., McCarthy J.S. Potencies of human immunodeficiency virus protease inhibitors in vitro against Plasmodium falciparum and in vivo against murine malaria. Antimicrobial Agents and Chemotherapy 2006, 50:639-648.
6. Borg-von Zepelin M., Beggah S., Boggian K., Sanglard D., Monod M. The expression of the secreted aspartil proteinases Sap4 to Sap6 from Candida albicans in murine macrophages. Molecular Microbiology 1998, 28:543-554.
7. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry 1976, 72:248-254.
8. Brower E.T., Bacha U.M., Kawasaki Y., Freire E. Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use. Chemical Biology and Drug Design 2008, 71:298-305.
9. Cassone A., De Bernardis F., Torosantucci A., Tacconelli E., Tumbarello M., Caud R. In vitro and In vivo anticandidal activity of human immunodeficiency virus protease inhibitors. Journal of Infectious Diseases 1999, 180:448-453.
10. Cruz I., Nieto J., Moreno J., Cañavate C., Desjeux P., Alvar J. Leishmania/HIV co-infections in the second decade. The Indian Journal of Medical Research 2006, 123:357-388.
11. De la Rosa R., Pineda J.A., Delgado J., Macías J., Morillas F., Mira J.A., Sánchez-Quijano A., Leal M., Lissen E. Incidence of and risk factors for symptomatic visceral leishmaniasis among human immunodeficiency virus type 1-infected patients from Spain in the era of highly active antiretroviral therapy. Journal of Clinical Microbiology 2002, 40:762-767.
12. Desjeux P., Alvar J. Leishmania/HIV co-infections: epidemiology in Europe. Annals of Tropical Medicine and Parasitology 2003, 1:3-15.
13. Dutta A., Sarkar D., Gurib-Fakim A., Mandal C., Chatterjee M. In vitro and in vivo activity of Aloe vera leaf exudate in experimental visceral leishmaniasis. Parasitology Research 2008, 102:1235-1242.
14. Fernández Cotarelo M.J., Abellán Martínez J., Guerra Vales J.M., Martínez Sánchez P., Gómez Rodrigo., de la Bárcena M., Salto Fernández E. Effect of highly active antiretroviral therapy on the incidence and clinical manifestations of visceral leishmaniasis in human immunodeficiency virus-infected patients. Clinical Infectious Diseases 2003, 37:973-977.
15. Folks T.M., Justement J., Kinter A., Dinarello C.A., Fauci A.S. Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line. Science 1987, 238:800-802.
16. Getti G., Durgadoss P., Domínguez-Carmona D., Martin-Quintal Z., Peraza-Sánchez S., Peña-Rodriguez L.M., Humber D. Leishmanicidal activity of Yucatecan medicinal plants on Leishmania species responsible for cutaneous leishmaniasis. Journal of Parasitology 2009, 95:456-460.
17. Giam C.Z., Boros I. In vivo and in vitro autoprocessing of human immunodeficiency virus protease expressed in Escherichia coli. Journal Biological Chemistry 1988, 263:14617-14620.
18. Hansen J., Billich S., Schulze T., Sukrow S., Moelling K. Partial purification and substrate analysis of bacterially expressed HIV protease by means of monoclonal antibody. The EMBO Journal 1988, 7:1785-1792.
19. Heeswijk R.P., Veldkamp A., Mulder J.W., Meenhorst P.L., Lange J.M., Beijnen J.H., Hoetelmans R.M. Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience. Antiviral Therapy 2001, 6:201-229.
20. Hornillos V., Saugar J.M., de la Torre B., Andreu D., Rivas L., Acuña A.U., Amat-Guerri F. Synthesis of 16-mercaptohexadecylphosphocholine, a miltefosine analog with leishmanicidal activity. Bioorganic and Medicinal Chemistry Letters 2006, 16:5190-5193.
21. Korting H.C., Schaller M., Eder G., Hamm G., Böhmer U., Hube B. Effects of the human immunodeficiency virus (HIV) proteinase inhibitors Saquinavir and Indinavir on in vitro activities of secreted aspartyl proteinases of Candida albicans isolates from HIV-infected patients. Antimicrobial Agents and Chemotherapy 1999, 43:2038-2042.
22. Mangoni M.L., Papo N., Saugar J.M., Barra D., Shai Y., Simmaco M., Rivas L. Effect of natural l- to d-amino acid conversion on the organization, membrane binding, and biological function of the antimicrobial peptides bombinins H†. Biochemistry 2006, 45:4266-4276.
23. Mastrolorenzo A., Rusconi S., Scozzafava A., Barbaro G., Supuran C.T. Inhibitors of HIV-1 protease: current state of the art 10 years after their introduction. From antiretroviral drugs to antifungal, antibacterial and antitumor agents based on aspartic protease inhibitors. Current Medicinal Chemistry 2007, 14:2734-2748.
24. Mosman T. Rapid colorimetric assay for cellular growth and survival; application to proliferation and cyotoxicity assay. The Journal of Immunological Methods 1983, 65:55-63.
25. Olivier M., Badaró R., Medrano F.J., Moreno J. The pathogenesis of Leishmania/HIV co-infection: cellular and immunological mechanisms. Annals of Tropical Medicine and Parasitology 2003, 1:79-98.
26. Pan A.A. Leishmania mexicana: serial cultivation of intracellular stages in a cell-free medium. Experimental Parasitology 1984, 58:72-80.
27. Pintado V., Martín-Rabadán P., Rivera M.L., Moreno S., Bouza E. Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non HIV infected patients. Medicine 2001, 80:54-73.
28. Pozio E., Goméz M. The Impact of HIV-protease inhibitors on opportunistic parasites. Trends in Parasitology 2005, 21:58-63.
29. Rabello A., Orsini M., Disch J. Leishmania/HIV co-infection in Brazil: an appraisal. Annals of Tropical Medicine and Parasitology 2003, 1:17-28.
30. Ramirez J.L., Guevara P. The ribosomal gene spacer as tool for the taxonomy of Leishmania. Molecular and Biochemical Parasitology 1987, 22:177-183.
31. Santos L.O., Marinho F.A., Altoé E.F., Vitório B.S., Alves C.R., Britto C., Motta M.C., Branquinha M.H., Santos A.L., d'Avila-Levy C.M. HIV aspartyl peptidase inhibitors interfere with cellular proliferation, ultrastructure and macrophage infection of Leishmania amazonensis. PLoS ONE 2009, 4:e4918.
32. Savoia D., Tiziano A., Tovo P. Antileishmanial activity of HIV protease inhibitors. The International Journal of Antimicrobial Agents 2005, 26:92-94.
33. Seelmeier S., Schmidt H., Turk V., von der Helm K. Human immunodeficiency virus has an aspartic-type protease that can be inhibited by pepstatin A. Proceedings of the National Academy of Sciences of the United States of America 1988, 85:6612-6616.
34. Skinner-Adams T.S., McCarthy J.S., Gardiner D.L., M Hilton P., Andrews K.T. Antiretrovirals as antimalarial agents. Journal of Infectious Diseases 2004, 190:1998-2000.
35. Smith R.E., Van Frank R.M. The use of amino acid derivatives of 4-methoxy-beta-naphthylamine for assay and subcellular localization of tissue proteinases. Frontiers in Bioscience 1975, 43:193-249.
36. Trudel N., Garg R., Messier N., Sundar S., Ouellette M., Tremblay M.J. Intracellular survival of Leishmania species that cause visceral leishmaniasis is significantly reduced by HIV-1 protease inhibitors. Journal of Infectious Diseases 2008, 198:1292-1299.
37. Valdivieso E., Dagger F., Rascón A. Leishmania mexicana: identification and characterization of an aspartyl proteinase activity. Experimental Parasitology 2007, 116:77-82.
38. World Health Organization, 1995. Report on the Consultative Meeting on Leishmania/HIV Co-infection. WHO/LEISH/95.35. World Health Organization, Geneva, Switzerland, pp. 1-14.